Beckman Coulter Obtains CE Mark for COVID-19 Antibody Test

June 18, 2020

Beckman Coulter said its Access SARS-CoV-2 IgG assay is now available in markets that accept the CE mark.

The assay detects immunoglobulin G (IgG) and targets antibodies that recognize the receptor-binding domain (RBD) of the spike protein which SARS-CoV-2 uses to bind to a human cell receptor. Antibodies that target the RBD may neutralize the virus and block it from entering the cell.

The company has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the U.S., and is now shipping to customers globally.

View today's stories